# Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Study · id `cardio:ct-nct02620163` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02620163](<https://clinicaltrials.gov/study/NCT02620163>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02620163

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 381 participants.

## Technical summary

Registry record NCT02620163. Randomized; double masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2016-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 381 participants (enrolled count; ClinicalTrials.gov record NCT02620163, source copy `cardio:ctgov-nct02620163-2024-11-12`, retrieved 2026-10-26)
- Started: 2015-12 (actual) (ClinicalTrials.gov record NCT02620163, source copy `cardio:ctgov-nct02620163-2024-11-12`, retrieved 2026-10-26)
- Primary completion: 2016-12 (actual) (ClinicalTrials.gov record NCT02620163, source copy `cardio:ctgov-nct02620163-2024-11-12`, retrieved 2026-10-26)
- Completion: 2016-12 (actual) (ClinicalTrials.gov record NCT02620163, source copy `cardio:ctgov-nct02620163-2024-11-12`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02620163, source copy `cardio:ctgov-nct02620163-2024-11-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02620163-2024-11-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
- Condition: Hypertension
- Intervention (Drug): telmisartan/amlodipine 40/5mg
- Intervention (Drug): YH22162 40/5/12.5 mg
- Intervention (Drug): telmisartan/amlodipine 80/5mg
- Intervention (Drug): YH22162 80/5/25 mg
- Intervention (Drug): telmisartan/amlodipine 40/5mg placebo
- Intervention (Drug): YH22162 40/5/12.5 mg placebo
- Intervention (Drug): telmisartan/amlodipine 80/5mg placebo
- Intervention (Drug): YH22162 80/5/25 mg placebo
- Lead sponsor: Yuhan Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Yuhan Corporation (`cardio:org-yuhan-corporation`)

## Provenance

Content hash: 18df5e9c80975a9100651590659c4f4f8f26764c65f9f5275881fc3bb7350ba7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
